Schrodinger Partners with Eli Lilly to Integrate TuneLab AI Platform into LiveDesign Software
核心洞察
Schrodinger announced a collaboration with Eli Lilly to integrate the pharmaceutical giant's AI-based TuneLab (搜索) platform into its LiveDesign (搜索) drug design software.
The integration will provide biotech companies direct access to Lilly's artificial intelligence platform to accelerate drug development processes.
Current LiveDesign (搜索) clients will gain access to TuneLab (搜索) in Q1 2025, with new users able to utilize the AI software by Q2 2025.
Schrodinger announced on Friday a strategic collaboration with Eli Lilly to integrate the pharmaceutical major's AI-based platform, TuneLab (搜索), into its drug designing software LiveDesign (搜索). The partnership aims to provide biotech companies with direct access to artificial intelligence tools that can accelerate drug development timelines.
Platform Integration Details
The integration of Lilly's TuneLab (搜索) into Schrodinger's LiveDesign (搜索) will enable biotechnology companies to leverage advanced AI capabilities for drug discovery. Schrodinger's cloud-based LiveDesign platform currently helps chemists design compounds and predict critical drug properties such as absorption and distribution, providing insights into how experimental drugs will behave in the human body.
According to Karen Akinsanya, Schrodinger's Chief Strategy Officer, current LiveDesign (搜索) clients will be able to access TuneLab (搜索) functionality in the first quarter of this year, while new users will have access to the AI software by the second quarter.
AI-Driven Drug Discovery Acceleration
Drug developers are increasingly adopting artificial intelligence for discovery and safety testing to achieve faster and more cost-effective results. This trend aligns with FDA initiatives to reduce animal testing requirements in the near future, creating additional incentives for AI-based approaches.
Eli Lilly launched TuneLab (搜索) last year as an AI and machine learning platform designed to provide biotech companies access to drug discovery models trained on years of the company's research data. The pharmaceutical giant has already established partnerships with several biotech companies to utilize its platform for drug development initiatives.
Industry Impact and Future Outlook
"More biotechs using the models means more diverse training data... Ultimately, this is about moving molecules through discovery faster for the patients who are waiting," said Aliza Apple, global head of Lilly TuneLab (搜索).
The collaboration represents a significant step in democratizing access to sophisticated AI tools that were previously available only to large pharmaceutical companies. By making TuneLab (搜索) accessible through Schrodinger's established LiveDesign (搜索) platform, smaller biotech companies can now leverage advanced machine learning capabilities without developing their own AI infrastructure.
The partnership underscores the growing importance of AI in pharmaceutical research and development, as companies seek to reduce the time and cost associated with bringing new therapies to market while maintaining rigorous safety and efficacy standards.